Its likely that patients felt ownership of equity could influence the researchers behavior in the trial, which might jeopardize the patients rights and welfare, he said.
In addition to their willingness to participate in the trial, the subjects reactions to the financial disclosures were also assessed as they related to level of surprise, confidence in the quality of the science, and trust of the researcher and the institution.
Interestingly, we found that trust seemed to be the most affected, although it didnt necessarily correlate with their willingness to participate, Weinfurt said. One-third of the respondents said the financial disclosures made them less trusting of the researcher or the institution, but further studies will be needed to really tease out the implications of this.
It is essential that clinical research is a trustworthy endeavor, so we need to think carefully about the implications of these findings, said Jeremy Sugarman, M.D., a professor of bioethics and medicine at the Johns Hopkins Berman Institute of Bioethics and senior author of the study.
The relationships between researchers and industry are becoming more complex, Weinfurt said, leading to greater interest and visibility for this issue as it relates to patients.
The Department of Health and Human Services, among other organizations, has issued a call to the scientific and medical communities to consider whether disclosing financial relationships between investigators and industry during the consent process would help protect the rights and welfare of patients. Our data can help answ
|Contact: Lauren Shaftel Williams|
Duke University Medical Center